Clinical trials: HIV Associated Lipodystrophy Syndrome.
HIV/AIDS, HIV Lipodystrophy Syndrome
Energy Expenditure of People Living With HIV/AIDS
Background: Several studies have reported increased resting energy expenditure (REE) in people living with HIV/AIDS possibly due to changes in body composition that occurs in HIV lipodystrophy syndrome.
- Trial name
- NCT02530827
- Testing
- use of lipid-lowering drugs.
- Volunteers
- 45 people
- Sponsor
- University of Sao Paulo General Hospital
HIV-Associated Lipodystrophy Syndrome, Insulin Resistance
Growth Hormone and/or Rosiglitazone for HIV-Associated Increased Abdominal Fat and Insulin Resistance
The purpose of the study is to determine if the combination of recombinant human growth hormone plus rosiglitazone (an insulin-sensitizing drug) is safe and more effective than either drug alone (or no active therapy) for the…
- Conditions
- HIV-Associated Lipodystrophy Syndrome, Insulin Resistance, HIV Infections, Metabolic Syndrome X
- Trial name
- NCT00130286
- Testing
- Rosiglitazone, Recombinant human growth hormone + rosiglitazone
- Where
- 4 sites in United States
- Volunteers
- 77 people
- Sponsor
- Weill Medical College of Cornell University
HIV Infections, HIV-Associated Lipodystrophy Syndrome
Evaluation of the Occurrence of Lipoatrophy in HIV-1 Infected Naive Patients
The aim of this randomized study is to compare the occurrence of lipoatrophy in HIV-1 infected, naive patients receiving either a nucleoside reverse transcriptase inhibitor (NRTI)-sparing antiretroviral therapy with…
- Trial name
- NCT00122668
- Testing
- non-nucleoside reverse transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, protease inhibitor
- Where
- France
- Volunteers
- 112 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
HIV Infections, Lipodystrophy
TH9507 in Patients With HIV-Associated Lipodystrophy
HIV lipodystrophy affects a significant proportion of patients treated with combination antiretroviral therapy (ART) and is characterized by excess visceral fat accumulation and loss of extremity and subcutaneous fat, in…
- Trial name
- NCT00123253
- Testing
- TH9507
- Where
- 42 sites in United States, Canada
- Volunteers
- 412 people
- Sponsor
- Theratechnologies
HIV Infections, Lipodystrophy
Treatment of Abnormal Adipose Tissue Accumulation in Human Immunodeficiency Virus (HIV) Patients
The primary objective of the study is to determine if Serostim® 4 mg administered daily for 12 weeks as treatment for the abnormal fat accumulation and distribution associated with HIV-associated Adipose Redistribution Syndrome…
- Trial name
- NCT00082628
- Testing
- Serostim® 4 mg, Serostim® 2 mg
- Where
- 31 sites in United States, Canada
- Volunteers
- 326 people
- Sponsor
- EMD Serono
HIV Infections, Lipodystrophy
Therapeutic Approaches to HAART-Induced Lipodystrophy
To determine the efficacy and safety of 4 therapeutic interventions on HAART-Induced lipodystrophy. The interventions are: 1) Dietary - the effect of a high carbohydrate vs.a high cis-monounsaturated fatty acid diet.
- Trial name
- NCT00461552
- Testing
- Leptin
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- University of Texas Southwestern Medical Center
Lipodystrophy Syndrome, HIV, Sarcopenia
Detraining in People Living With HIV/AIDS
The goal of this study was to evaluate the effect of detraining in the components of physical aptitude of people living with HIV/Aids (PVHA).
- Trial name
- PVHA (NCT03075332)
- Testing
- combined training
- Where
- 2 sites in Brazil
- Volunteers
- 2 people, healthy volunteers welcome
- Sponsor
- Universidade Federal do Rio Grande do Norte
HIV-Associated Lipodystrophy Syndrome, HIV Infections
Effect of Pioglitazone on HIV-1 Related Lipoatrophy: a Randomized, Double Blind, Placebo-Controlled Trial in 130 Patients
The aim of this randomized study is to compare the effect of pioglitazone versus placebo on change in limb fat in HIV 1-infected patients treated with antiretroviral therapy for at least 6 months and with clinical lipoatrophy.
- Trial name
- NCT00148850
- Testing
- Pioglitazone
- Where
- France
- Volunteers
- 130 people
- Sponsor
- French National Agency for Research on AIDS and Viral Hepatitis
HIV-Associated Lipodystrophy Syndrome
Strategies of Interruption/Reinitiation of Antiretroviral Therapy in HIV-Infected Patients With Lipodystrophy
Aim: To assess the safety on the progression of HIV infection and the efficacy on the evolution of metabolic parameters and body fat of either viral load- or CD4 cell-driven strategies of intermittent treatment in chronically…
- Trial name
- NCT00646984
- Testing
- Standard continuous antiretroviral therapy, CD-4 guided therapy interruption, Viral load driven treatment interruption
- Where
- Spain
- Volunteers
- 147 people
- Sponsor
- Hospital Clinic of Barcelona
HIV Infections, HIV-Associated Lipodystrophy Syndrome
MEDICLAS Study (Metabolic Effects of Different Classes of AntiretroviralS)
This is a randomized prospective study into metabolic adverse events during different types of initial antiretroviral therapy in HIV-1-infected men.
- Trial name
- NCT00122226
- Testing
- Lopinavir/ritonavir + zidovudine + lamivudine, Lopinavir/ritonavir + nevirapine
- Where
- 13 sites in Finland, Netherlands and 2 more
- Volunteers
- 50 people
- Sponsor
- Amsterdam UMC, location VUmc
Lipodystrophy, HIV Infections
TH9507 Extension Study in Patients With HIV-Associated Lipodystrophy
Assessing the Efficacy and Long-Term Safety of a 2 mg dose of TH9507, a Growth Hormone-Releasing Factor Analog, in HIV Subjects with Excess Abdominal Fat Accumulation
- Trial name
- NCT00608023
- Testing
- Tesamorelin
- Where
- 47 sites in United States, Belgium and 4 more
- Volunteers
- 263 people
- Sponsor
- Theratechnologies
HIV-Associated Lipodystrophy Syndrome
Comparing a Nucleoside-Analogue-Sparing Regimen and a Protease-Inhibitor-Sparing Regimen in HIV Infected Patients
Highly active antiretroviral therapy (HAART) has improved the long time survival of HIV infected individuals. However an increasing number of HIV-patients have developed metabolic and morphological alterations including…
- Trial name
- NCT00135460
- Testing
- nucleoside analogue sparing HAART regimen
- Where
- 5 sites in Denmark
- Volunteers
- 100 people
- Sponsor
- Danish HIV Research Group
HIV-Associated Lipodystrophy Syndrome
Psychological Morbidity and Facial Volume in HIV Lipodystrophy: Quantification of Treatment Outcome
The hypotheses of this study were that: 1. HIV lipodystrophy is associated with psychological morbidity relating to body image, anxiety and depression. 2.
- Trial name
- NCT01359917
- Volunteers
- 50 people
- Sponsor
- NHS Lothian
HIV Infection, Antiretroviral Side Effects
Polyacrylamide Hydrogel Injection in HIV-related Lipoatrophy
Combined antiretroviral therapy (cART) is associated with facial lipoatrophy, which is potentially stigmatizing for HIV-positive patients.
- Conditions
- HIV Infection, Antiretroviral Side Effects, Lipodystrophy Syndrome Related to HIV Infection
- Trial name
- LIPOPHILL (NCT01077765)
- Testing
- Eutrophill
- Where
- France
- Volunteers
- 100 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
HIV-Associated Lipodystrophy Syndrome
Study of Reyataz in HIV-infected Patients With Lipodystrophy Syndrome
The purpose of this clinical research study is to learn if human immunodeficiency virus (HIV)-infected subjects with abdominal fat accumulation on their highly active antiretroviral treatment (HAART) regimen have better changes…
- Trial name
- NCT00135356
- Testing
- Atazanavir (ATV) + ritonavir (RTV), continuation of backbone 2 nucleoside reverse transcriptase inhibitor (NRTIs), continuation of current HAART (boosted protease inhibitor [PI] combination + 2 NRTIs)
- Where
- 30 sites in United States, Canada and 7 more
- Volunteers
- 219 people
- Sponsor
- Bristol-Myers Squibb
HIV Facial Lipoatrophy
Voluma Filler Agent For The Treatment of HIV-associated Facial Lipoatrophy
The purpose of this study is to test the safety of Voluma and see what effects it has on HIV facial lipoatrophy. The hypothesis is that Voluma will be safe, efficacious and positively impact the quality-of-life in the treatment…
- Trial name
- NCT02342223
- Testing
- Voluma
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Jared Jagdeo, MD, MS
HIV-Associated Focal Segmental Glomerulosclerosis, HIV-Associated Collapsing Glomerulopathy
Evaluation of Albuminuria HIV-Infected Patients
This study will examine the following: 1) how common albuminuria and proteinuria are among HIV-positive patients, 2) what causes albuminuria or proteinuria in these patients and 3) whether the condition becomes more severe over…
- Conditions
- HIV-Associated Focal Segmental Glomerulosclerosis, HIV-Associated Collapsing Glomerulopathy, Proteinuria, Albuminuria
- Trial name
- NCT00524992
- Where
- 2 sites in United States
- Volunteers
- 252 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
HIV-associated Lipodystrophy Syndrome
An Study to Investigate the Recovery, Excretion, and Pharmacokinetics of 14C-GSK1265744 Administered as a Single Oral Dose and a Study to Describe the Pharmacokinetics of a Supratherapeutic Dose of GSK1265744 in Healthy Adult Subjects
This will be a two-part study in healthy adults. Part A is a phase 1, non-randomized, open label, single-dose, single-centre mass balance study utilizing a radiolabeled dose to investigate the recovery, excretion, and…
- Trial name
- NCT01848340
- Testing
- GSK1265744B (sodium salt) containing 14C-GSK1265744B, 150 mg GSK1265744B
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- ViiV Healthcare
HIV Lipodystrophy
Leptin for Abnormal Lipid Kinetics in HIV Lipodystrophy Syndrome
"HIV lipodystrophy syndrome" (HLS) is characterized by loss of fat in the arms and legs, with increase in fat in the abdomen, and abnormal blood lipid levels.
- Trial name
- NCT01511016
- Testing
- Human recombinant leptin ("metreleptin")
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- Baylor College of Medicine
HIV Associated Lipodystrophy Syndrome., HIV
Switching From Zidovudine to an NNRTI or Lopinavir/Ritonavir in Patients Treated With Zidovudine/ Lamivudine/Abacavir.
Highly active antiretroviral therapy (HAART) has improved the long time survival of HIV infected individuals. However an increasing number of HIV-patients have developed metabolic and morphological alterations including…
- Conditions
- HIV Associated Lipodystrophy Syndrome., HIV, Hypercholesterolemia, Lipoatrophy
- Trial name
- NCT00139178
- Testing
- Different HAART regimens
- Where
- 4 sites in Denmark
- Volunteers
- 100 people
- Sponsor
- Danish HIV Research Group